Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Cubist Pharmaceuticals |
---|---|
Information provided by: | Cubist Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00538694 |
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
Condition | Intervention | Phase |
---|---|---|
Pneumonia, Bacterial |
Drug: daptomycin |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Parallel Assignment |
Official Title: | A Randomized, Double-Blind, Phase III, Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | DAP-00-05 |
Study First Received: | October 1, 2007 |
Last Updated: | October 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00538694 |
Health Authority: | United States: Food and Drug Administration |
Moderate to severe community-acquired acute bacterial pneumonia due to S. Pneumoniae |
Daptomycin Bacterial Infections Respiratory Tract Infections Respiratory Tract Diseases |
Lung Diseases Pneumonia, Bacterial Ceftriaxone Pneumonia |
Anti-Infective Agents Anti-Bacterial Agents Therapeutic Uses Pharmacologic Actions |